Diverging vasorelaxing effects of C-type natriuretic peptide in renal resistance arteries and aortas of GC-A-deficient mice.
This study aimed to characterize the vasorelaxing effects of ANP, BNP and CNP in isolated renal resistance arteries (RRA) from wild-type mice and mice with either systemic (GC-A -/-) or smooth muscle-restricted deletion of GC-A (SMC GC-A KO). In RRA from wild-type (GC-A +/+) mice natriuretic peptides (NP) induced concentration-dependent vasorelaxations with the rank order of potency ANP>BNP>CNP. In RAA obtained from mice with systemic or smooth muscle-restricted deletion of GC-A, the effects of ANP and BNP were abolished. In contrast, CNP induced concentration-dependent vasorelaxations of GC-A -/- and SMC GC-A KO RRA. However, the efficacy of CNP for vasorelaxation was markedly diminished compared with wild-type RRA. Such changes in CNP responsiveness did not affect large arteries as the aorta and they were not due to vascular changes secondary to chronic arterial hypertension in GC-A -/- mice. Unaltered vasorelaxing effects of acetylcholine and sodium nitroprusside demonstrated unaltered function of downstream targets regulated by cGMP in vascular smooth muscle. An increased expression of the clearance receptor (NPR-C) or diminished expression of GC-B were not found to account for the differences in CNP responsiveness. In conclusion, observations in isolated aortic rings do not necessarily allow conclusions concerning the physiology of natriuretic peptides in the smaller resistance size arteries. Changes at the GC-B receptor level are likely to explain the diminished responsiveness of GC-A-deficient RRA to CNP.
Steinmetz
Martin
M
Medizinische Klinik und Poliklinik D., Universitätsklinikum Münster, Albert-Schweitzer Strasse 33, 48129 Münster, Germany. steinme@uni-muenster.de
Potthast
Regine
R
Sabrane
Karim
K
Kuhn
Michaela
M
D000109:Acetylcholine / Q000378:metabolism / Q000494:pharmacology; D000818:Animals; D001011:Aorta / Q000473:pathology*; D009320:Atrial Natriuretic Factor / Q000378:metabolism; D017931:DNA Primers / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D017353:Gene Deletion; D006162:Guanylate Cyclase / Q000378:metabolism; D007668:Kidney / Q000378:metabolism* / Q000473:pathology; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D009131:Muscle, Smooth, Vascular / Q000473:pathology; D020098:Natriuretic Peptide, C-Type / Q000235:genetics* / Q000502:physiology*; D009599:Nitroprusside / Q000494:pharmacology; D010455:Peptides; D012333:RNA, Messenger / Q000378:metabolism; D017461:Receptors, Atrial Natriuretic Factor / Q000378:metabolism; D012077:Renal Artery / Q000473:pathology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000099242:Atrial Natriuretic Factor Receptor B
D000109:Acetylcholine; D009320:Atrial Natriuretic Factor; D017931:DNA Primers; D006162:Guanylate Cyclase; D020098:Natriuretic Peptide, C-Type; D009599:Nitroprusside; D010455:Peptides; D012333:RNA, Messenger; D017461:Receptors, Atrial Natriuretic Factor; D000099242:Atrial Natriuretic Factor Receptor B; C091715:atrial natriuretic factor receptor A